DK2854789T3 - Genotype- eller fænotype-baserede lægemiddelformuleringer - Google Patents

Genotype- eller fænotype-baserede lægemiddelformuleringer Download PDF

Info

Publication number
DK2854789T3
DK2854789T3 DK13725157.5T DK13725157T DK2854789T3 DK 2854789 T3 DK2854789 T3 DK 2854789T3 DK 13725157 T DK13725157 T DK 13725157T DK 2854789 T3 DK2854789 T3 DK 2854789T3
Authority
DK
Denmark
Prior art keywords
genotype
phenotype
pharmaceutical formulations
based pharmaceutical
formulations
Prior art date
Application number
DK13725157.5T
Other languages
English (en)
Inventor
Stefan Willmann
Kristin Dickschen
Thomas Eissing
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK2854789T3 publication Critical patent/DK2854789T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK13725157.5T 2012-06-01 2013-05-27 Genotype- eller fænotype-baserede lægemiddelformuleringer DK2854789T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170401.9A EP2668945A1 (de) 2012-06-01 2012-06-01 Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
PCT/EP2013/060824 WO2013178565A1 (de) 2012-06-01 2013-05-27 Genotyp- bzw. phänotyp-basierte arzeimittelformulierungen

Publications (1)

Publication Number Publication Date
DK2854789T3 true DK2854789T3 (da) 2019-09-16

Family

ID=48520964

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13725157.5T DK2854789T3 (da) 2012-06-01 2013-05-27 Genotype- eller fænotype-baserede lægemiddelformuleringer

Country Status (23)

Country Link
US (3) US10285958B2 (da)
EP (2) EP2668945A1 (da)
JP (2) JP6096289B2 (da)
KR (1) KR102129043B1 (da)
CN (2) CN104507464A (da)
AR (2) AR091234A1 (da)
AU (1) AU2013269793B2 (da)
BR (1) BR112014030059B1 (da)
CA (1) CA2875189C (da)
DK (1) DK2854789T3 (da)
ES (1) ES2744306T3 (da)
HK (1) HK1207296A1 (da)
HU (1) HUE045699T2 (da)
IL (1) IL235988B (da)
MX (1) MX370304B (da)
NZ (1) NZ702849A (da)
PL (1) PL2854789T3 (da)
PT (1) PT2854789T (da)
RU (1) RU2683260C2 (da)
SA (1) SA113340607B1 (da)
SG (2) SG10201610072UA (da)
TW (1) TWI644666B (da)
WO (1) WO2013178565A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes
WO2025194145A1 (en) * 2024-03-14 2025-09-18 Duke University Compositions comprising hepatocytes and methods of treating metabolic liver diseases and disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317546C (en) * 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5580728A (en) 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6760708B1 (en) 1999-08-19 2004-07-06 Dell Products L.P. Method and system for migrating stored data to a build-to-order computing system
EP1248832A4 (en) 2000-01-21 2004-07-07 Variagenics Inc IDENTIFICATION OF THE GENETIC COMPONENTS OF A MEDICINE REACTION
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
CN102349927A (zh) * 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
DE10345836A1 (de) 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen
JP4732683B2 (ja) 2003-12-29 2011-07-27 ユニバーサル・バイオ・リサーチ株式会社 標的物質の検出方法
WO2005092314A1 (en) * 2004-03-18 2005-10-06 Istituto Nazionale Per Lo Studio E La Cura Del Tum 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
US7805282B2 (en) 2004-03-30 2010-09-28 New York University Process, software arrangement and computer-accessible medium for obtaining information associated with a haplotype
DE102004025534A1 (de) 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung
US8024128B2 (en) 2004-09-07 2011-09-20 Gene Security Network, Inc. System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US8147615B2 (en) 2004-11-05 2012-04-03 Infineon Technologies Ag Method of fabricating semiconductor cleaners
AU2006252394A1 (en) * 2005-06-02 2006-12-07 Biovail Laboratories International S.R.L. Modified-release composition of at least one form of venlafaxine
US20070122824A1 (en) 2005-09-09 2007-05-31 Tucker Mark R Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
US20110010099A1 (en) 2005-09-19 2011-01-13 Aram S Adourian Correlation Analysis of Biological Systems
RU2318508C2 (ru) * 2005-12-28 2008-03-10 Всеволод Иванович Киселев Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы
FR2896896B1 (fr) 2006-02-02 2009-09-25 Commissariat Energie Atomique Procede de classification d'evenements ou d'etats en deux etapes
DE102006028232A1 (de) 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
DK2101731T3 (da) 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc Endoxifen til anvendelse ved behandling af cancer
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
US20110113002A1 (en) 2008-02-26 2011-05-12 Kane Michael D Method for patient genotyping
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
WO2009137543A2 (en) * 2008-05-06 2009-11-12 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
JP4517312B2 (ja) * 2008-07-08 2010-08-04 ソニー株式会社 メモリアクセス制御装置および撮像装置
US20110136913A1 (en) * 2008-08-19 2011-06-09 Goetz Matthew P Assessing and treating breast cancer patients
US8275442B2 (en) 2008-09-25 2012-09-25 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
WO2010096834A2 (en) 2009-02-23 2010-08-26 Indiana University Research & Technology Corporation Materials and methods for treating patients with tamoxifen
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
US9372198B2 (en) 2010-06-17 2016-06-21 Aradigm Corporation Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
WO2012025942A1 (en) * 2010-08-26 2012-03-01 Ipca Laboratories Limited Methods for the treatment or prophylaxis of thrombosis or embolism
MX344435B (es) * 2011-06-27 2016-12-14 Ipca Laboratories Ltd * Compuestos antitromboticos.
MX357392B (es) 2012-04-02 2018-07-06 Berg Llc Ensayos basados en interrogatorios celulares y uso de los mismos.
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9417221B2 (en) 2013-08-27 2016-08-16 International Business Machines Corporation Food steganography

Also Published As

Publication number Publication date
MX2014014596A (es) 2015-03-03
SG10201610072UA (en) 2017-01-27
AR118842A2 (es) 2021-11-03
JP2015519350A (ja) 2015-07-09
HUE045699T2 (hu) 2020-01-28
CA2875189C (en) 2020-09-22
AR091234A1 (es) 2015-01-21
SG11201407791VA (en) 2015-01-29
AU2013269793B2 (en) 2018-03-01
JP2017048234A (ja) 2017-03-09
EP2854789B1 (de) 2019-06-26
TWI644666B (zh) 2018-12-21
IL235988A0 (en) 2015-01-29
US10285958B2 (en) 2019-05-14
US20150174082A1 (en) 2015-06-25
PT2854789T (pt) 2019-09-18
IL235988B (en) 2018-11-29
HK1207296A1 (en) 2016-01-29
SA113340607B1 (ar) 2018-05-09
BR112014030059B1 (pt) 2022-12-06
BR112014030059A2 (pt) 2017-07-25
CN104507464A (zh) 2015-04-08
JP6096289B2 (ja) 2017-03-15
KR102129043B1 (ko) 2020-07-01
US20170326081A1 (en) 2017-11-16
RU2683260C2 (ru) 2019-03-27
US20170326080A1 (en) 2017-11-16
NZ702849A (en) 2016-09-30
AU2013269793A1 (en) 2015-01-22
WO2013178565A1 (de) 2013-12-05
PL2854789T3 (pl) 2019-12-31
CN110075097A (zh) 2019-08-02
ES2744306T3 (es) 2020-02-24
RU2014154140A (ru) 2016-07-27
EP2668945A1 (de) 2013-12-04
EP2854789A1 (de) 2015-04-08
MX370304B (es) 2019-12-09
CA2875189A1 (en) 2013-12-05
TW201400109A (zh) 2014-01-01
KR20150022894A (ko) 2015-03-04

Similar Documents

Publication Publication Date Title
CY2022027I1 (el) Παραγωγα βενζιμιδαζολο-προλινης
PT3725778T (pt) Formulações de enzalutamida
DK3117837T3 (da) Antistofformuleringer
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
BR112014003052A2 (pt) composições farmacêuticas
PT2854768T (pt) Composições farmacêuticas de pemetrexed
CO6930367A2 (es) Composiciones farmaceúticas
GT201200303A (es) Formulaciones farmacéuticas
CO6940426A2 (es) Formulaciones farmacéuticas
EP2934132A4 (en) DISINFECTANT
PT2931313T (pt) Formulações de solução de anticorpos anti-il-23p19 modificados
DK2897594T3 (da) Farmaceutisk sammensætning
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
HRP20171889T1 (hr) Formulacije kombinacije darunavira
DK2815752T3 (da) Oral farmaceutisk sammensætning
CL2014003283A1 (es) Formulación farmacéutica.
EP2934482A4 (en) ADMINISTRATIVE FORMULATIONS
DK2877155T3 (da) Opioidformuleringer
EP2832223A4 (en) HERBICIDE COMPOSITION
EP2883547A4 (en) MEDICINE
FR2988426B1 (fr) Plate-forme inter-aubes
FR2988427B1 (fr) Plate-forme inter-aubes
PL2908835T3 (pl) Stabilne formulacje
DK2931042T3 (da) Anthracyclinformuleringer
DK2672817T3 (da) Forbedrede insekticide formuleringer